Anaemia in Developing Countries: Burden and Prospects of Prevention and Control by Kayode O. Osungbade & Adeolu O. Oladunjoye
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Anaemia in Developing Countries: Burden  
and Prospects of Prevention and Control 
Kayode O. Osungbade1,2,* and Adeolu O. Oladunjoye1,2 
1Department of Health Policy and Management 
Faculty of Public Health 
College of Medicine and University College Hospital 
University of Ibadan and 
2Department of Community Medicine 
University College Hospital, Ibadan 
Nigeria 
1. Introduction 
Anaemia constitutes a public health problem in developing countries. Worldwide, about 2 
billion people are estimated to suffer from anaemia and it is reported to account for three-
quarters of 1 million deaths a year in Africa and South-East Asia. The underlying causes of 
anaemia are many, varied and largely preventable; these include nutritional deficiencies, 
infections and haemoglobin disorders. 
Cost-effective interventions against anaemia are well documented in the literature. 
However, there are constraints to diagnosis, treatment and prevention in resource-poor 
settings of developing countries. Effective management of anaemia includes treatment of the 
underlying cause, restoration of the haemoglobin concentration to normal levels, and 
prevention and treatment of complications, among others. Suggested strategies aimed at 
preventing anaemia focused on the major underlying causes in developing countries.  
2. Background 
Anaemia is the reduction in the haemoglobin concentration of the peripheral blood below the 
normal range expected for age and sex of an individual.(1)  The World Health Organisation 
(WHO) defines anaemia as a hemoglobin value below 13 g/dl in men over 15 years of age, 
below 12 g/dl in non pregnant women over 15 years, and below 11 g/dl in pregnant 
women.(2) It is a condition in which the number of red blood cells or their oxygen carrying 
capacity is insufficient to meet physiologic needs and this varies for age, sex, altitude and 
pregnancy status.(3)  However, the determination of hemoglobin concentration should always 
take the state of hydration and altitude of residence of an individual into consideration.(1) 
Anaemia is a global health problem in both developing and developed countries with major 
consequences on human health as well as social and economic development.(4) Anaemia is 
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the world’s second leading cause of disability.(3) Worldwide, the World Health 
Organisation (WHO) estimated the number of anaemic persons to be about 2 billion and 
approximately 50% of all cases can be attributed to iron deficiency.(5) Anaemia is 
responsible for about 1 million death a year, out of which three-quarters occur in Africa and 
South-East Asia.(6) Anaemia affects over half of preschool age children and pregnant 
women in developing countries, and at least 30-40% in industrialized countries.(3) 
Nevertheless, it is apparent that the prevalence of anaemia in developing countries is about 
four times more than developed countries.(7) In view of the above, this chapter highlights 
the burden of anaemia in the population and discusses its causes in developing countries. 
Furthermore, the chapter reviews the prospects and challenges of diagnosis of underlying 
causes, treatment and prevention in the developing countries. 
3. Methods 
We reviewed literature using key words of the thrust of the paper; hence, search terms such 
as prevalence, burden, causes, treatment and prevention of anaemia in developing countries 
were used. Cross sectional, observational and randomized control trials’ literature on the 
subject published between 2000 and 2010 served as the main sources of information. 
Commonly used medical databases such as PubMed (Medline), AJOL and Google Scholar 
were searched as appropriate; in addition, Cochrane Library was used to source for 
systematic reviews on the subject matter. 
4. Results 
4.1 Burden of anaemia in developing countries 
The most vulnerable groups in the population are children and pregnant women, while 
others such as the non pregnant women and the elderly are next affected. An estimated 10-
20% of preschool age children in developed countries and 30-80% in developing countries 
are anaemic at 1 year of age.(8) The consequences of anaemia in children are inimical as it 
affects their cognitive performance, behaviour and physical growth. Children who suffer 
from anaemia have delayed psychomotor development and impaired performance of tests; 
in addition, they experience impaired coordination of language and motor skills, equivalent 
to a 5 to 10 points deficit in intelligent quotient (IQ).(5)  
The World Health Organisation (WHO) estimated that 56% of all pregnant women in 
developing countries are anaemic.(9) In Southern Asia, the prevalence of anaemia in 
pregnancy is about 75% in contrast to what obtains in North America and Europe with 
about 17% prevalence. Furthermore, 5% of pregnant women suffer from severe anaemia in 
the worst affected parts of the world.(9)  
The consequences of anemia in women are enormous as the condition adversely affects both 
their productive and reproductive capabilities. First, anaemia reduces their energy and 
capacity for work (10), and can therefore threaten household food security and income. 
Second, severe anaemia in pregnancy impairs oxygen delivery to the fetus and interferes 
with normal intra-uterine growth, thereby resulting in intrauterine growth retardation, still 
birth, low birth weight and neonatal deaths.(10-11) Therefore, anaemia is highly 
contributory to poor pregnancy and birth outcomes in developing countries as it 
predisposes to premature delivery, increased perinatal mortality and increased risk of death 
during delivery and postpartum (10).  
www.intechopen.com
 
Anaemia in Developing Countries: Burden and Prospects of Prevention and Control 
 
117 
Worldwide, it is estimated that about 20% of maternal deaths are caused by anaemia; in 
addition, anaemia contributes partly to 50% of all maternal deaths.(12) Similar situation is 
found in sub-Saharan Africa where anaemia is reportedly accounted for about 20% of all 
maternal deaths brought about through three main mechanisms.(13) First, anaemia resulting 
from blood loss during or after childbirth makes women more susceptible to deaths by 
lowering their haematological reserve. Second, severe anaemia is associated with increased 
susceptibility to infection due to lowered resistance to disease; and third, haemoglobin (Hb) 
level of less than 4 g/dl is associated with high risk of cardiac failure and death particularly 
during delivery or soon after, if prompt intervention is not instituted.(14-15) 
In terms of lost years of healthy life, iron deficiency anemia causes 25 million cases of 
Disability Adjusted Life Years (DALYs); this accounts for 2.4% of the total global DALYs.(3) 
Physical and cognitive losses due to iron deficiency anaemia cost developing countries up to 
4.05% losses in gross domestic product per annum(16), thereby stalling social and economic 
development. In the World Health Organisation (WHO)/World Bank rankings, Iron 
Deficiency Anaemia (IDA) is the third leading cause of disability-adjusted life years lost for 
females’ aged 15–44 years.(17-18) 
4.2 Common causes of anaemia in developing countries 
Most often, anaemia co-exists with an underlying disease and rarely occurs on its own. The 
commonest causes of anaemia in developing countries, particularly among the most 
vulnerable groups (pregnant women and preschool age children) are nutritional disorders 
and infections.  
4.2.1 Iron deficiency 
Iron Deficiency Anaemia (IDA) is an underlying risk factor for maternal and perinatal 
mortality and morbidity; it is estimated to be associated with 115,000 of the 510,000 maternal 
deaths (i.e. 22%) and 591,000 of the 2,464,000 perinatal deaths (i.e. 24%) occurring annually 
around the world.(19) Iron is an essential component of haemoglobin (Hb), which is required 
for basic cellular function in all human tissues, particularly muscle, brain and red blood 
cells.(20) Therefore, deficiency of iron in the body can lead to anaemia in any age group. Iron 
deficiency anaemia (IDA) occurs when iron deficiency is sufficiently severe enough to 
diminish erythropoiesis, thereby leading to a decrease in the number of red cells in the blood 
and resulting in the development of anaemia.(21) However, mild-to-moderate forms of iron 
deficiency can occur in which the affected person is yet to become anaemic, but tissues are 
functionally iron deficient.(5) It is generally assumed that 50% of cases of anaemia are due to 
iron deficiency(5),  but this may vary within population groups or environment.  
The risk factors for IDA include a low intake of iron, poor absorption of iron from diets high 
in phytate or phenolic compounds, and early period of life when iron requirements are 
expectedly high. (4) Similarly, iron requirements are highest for pregnant women - 1.9 
mg/1,000 kcal of dietary energy in the second trimester and 2.7 mg/1,000 kcal in the third 
trimester. These are followed by iron requirements in infants (1.0 mg), adolescent girls (0.8 
mg), adolescent boys (0.6 mg), non pregnant women (0.6 mg), preschool and school age 
children (0.4mg), and adult men (0.3mg).(22)  
Sources of dietary iron include meat, fish and poultry; other sources, though in less 
quantity, are cereals, dairy products, fruits and vegetables. About 40% of iron content of 
meat, fish and poultry is in the haem form, out of which about 25% is absorbed;(7) whereas 
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only about 2 - 5% of total iron is absorbed from cereals and legumes. Therefore, these foods 
have a major influence on iron status.(23) Unfortunately, intakes of these foods especially 
meat, fish and poultry are low among people of low socio-economic status. Furthermore, 
some of the foods are avoided or observed as taboos for religious or cultural reasons in 
certain communities of developing countries.  
Inadequate absorption of dietary iron is highly contributory to the high prevalence of 
anaemia in the developing countries of Asia and other regions, except where it is caused by 
infections such as hookworm and malaria.(7) Poor absorption of dietary iron can be due to 
substances which interfere with its absorption such as proton pump inhibitors, calcium 
supplements and dairy products.(24)  
4.2.2 Micronutrient deficiency 
Evidence abounds that haemoglobin (Hb) concentration of persons with Vitamin A 
deficiency (VAD) increases by about 10 g/L when vitamin A supplements are provided.(25) 
Studies also suggest that vitamin A can improve hematologic indicators and enhance the 
efficacy of iron supplementation.(26) Thus, it is suggestive that Vitamin A deficiency (VAD) 
can predispose to anaemia.  
It is reported that riboflavin deficiency may be quite common in developing countries where 
intake of animal products is low, and especially during seasons when there is less intake of 
vegetables.(7) Vitamin B12 is necessary for the synthesis of red blood cells and its 
deficiencies have been associated with megaloblastic anemia.(17) Therefore, diets with little 
or no animal protein, as it is often the case in the developing world, coupled with 
malabsorption related to parasitic infections of the small intestine, might result in Vitamin B 
12 deficiency.(17)  
Folic acid is also essential for the formation and maturation of red blood cells and necessary 
for cell growth and repair. Deficiency of folate reduces the rate of DNA synthesis with 
consequent impaired cell proliferation and intramedullary death of resulting abnormal cells; 
this shortens the lifespan of circulating red blood cells and results in anaemia.(27) There is, 
however, little evidence that folic acid deficiency may be a public health problem in many 
developing countries. 
4.2.3 Infections 
4.2.3.1 Malaria 
It is now estimated that malaria is responsible for 1.2 million deaths annually and 2.9% of 
total DALYs in low and middle income countries.(28) About 35% of children with malaria in 
Africa have anaemia.(29) In sub-Saharan Africa, it is estimated that between 200,000 and 
500,000 pregnant women develop severe anemia as a result of malaria.(9) P. falciparum 
malaria in pregnancy is the primary cause of up to 10,000 maternal anaemia related deaths 
in sub-Saharan Africa annually.(30)  
Malaria, especially by the protozoon Plasmodium falciparum, causes anaemia by rupturing 
red blood cells and suppressing production of red blood cells.(31) However, this cannot be 
explained simply by the direct destruction of parasitized red blood cells at the time of 
release of meroziotes.(32) Decreased red cell production results from marrow hypoplasia 
seen in acute infection and dyerythropoiesis.(33) Plasmodium falciparum is the primary cause 
of severe malaria in regions of the world where malaria is endemic, especially sub-Sahara 
Africa .(7)  
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4.2.3.2 Parasitic infestation 
Helminthes such as flukes, hookworm and whipworm cause chronic blood loss, and 
consequently iron loss.(34) These parasitic infestations are known to cause chronic 
haemorrhage and iron deficiency, resulting in the development of anaemia.(35) Blood loss 
caused by helminthiasis put the mother, fetus and child at risk of iron deficiency, which 
could lead to anaemia.(36) For example, the trematode, Schistosomia haematobium (fluke), 
predisposes to a significant urinary blood loss in severe infections and infected persons may 
present with terminal heamaturia, which continues for as long as it is not treated and then 
results in anaemia. Whereas, Schistosomia mansoni eggs can rupture the intestinal lining and 
result in the leakage of blood, other fluids and nutrients into the lumen.(34)  
Hookworm infestation produces a high degree of long-term morbidity by causing iron 
deficiency anemia.(17) The extent to which this deficiency occurs depends on the host’s iron 
status, the infecting parasites, and the intensity and duration of infection.(36) Blood loss is 
caused primarily by coagulase released by the parasite and it is responsible for continuous 
blood loss in the stool.(17) For example, Ancylostoma duodenale is estimated to cause up to 
0.25 ml of blood loss per worm per day.(30)  
A hookworm burden of 40–160 worms (depending on the iron status of the host) is 
associated with iron deficiency anemia.(37) Several studies in developing countries 
observed that 51% of anaemic children were iron deficient and if hookworm infection could 
be reduced by as much as 25%, it would reduce iron deficiency anaemia by 35% and severe 
anaemia by 73%.(31, 38) The nematode, Trichuris trichiura (whipworm) causes anaemia if the 
worm burden is heavy(31) and colonic lesions are associated with bleeding or there is a 
chronic reduction in food and micro-nutrient intake caused by anorexia-inducing effects of 
tumor necrosis factor-α released in response to the infection.(39-40)  
4.2.3.3 Human Immuno-deficiency Virus infection (HIV) 
Developing countries are the worst hit by the HIV pandemic, which accounts for 22.5 million 
people (68% of global total) in sub-Saharan Africa and 4.9 million people (15% of global total) 
in Asia living with HIV/AIDS in 2009.(41) In 2009, 1.3 million Africans died of HIV and this 
constituted 72% of the global total.(42) Anaemia is a frequent complication among HIV-
positive individuals and it has been associated with a rapid HIV disease progression and 
mortality.(43) The predominant cause of anaemia in the context of HIV is anaemia of 
inflammation; this is also known as anemia of chronic disease, which is characterized by 
decreased red blood cell production through a series of mechanisms mediated, in part, by pro-
inflammatory cytokines such as tumor necrosis factor-α and interleukin-6.(17)  
Studies have also shown that zidovudine (AZT) causes anaemia in pregnant women as early 
as four weeks of commencing therapy.(44) The cause of anaemia in HIV-positive patients is, 
therefore, multi-factorial and includes infections, neoplasm, dietary deficiencies, blood loss, 
medications and antibodies to antiretroviral agents.(45-46)  In addition, bone marrow 
suppression, especially the erythroid lines, by the AIDS virus is also known to cause 
anaemia in affected persons.(47) 
4.3 Sickle cell diseases and thalassemia 
About 5% of the world’s population carries the genes responsible for 
haemoglobinopathies.(48) Sickle cell disease is an inherited disorder of hemogblobin and it 
is among the most common genetic diseases in the world.(17) Each year, about 300,000 
infants are born with major haemoglobin disorders – including more than 200,000 cases of 
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sickle-cell anaemia in Africa.(48) It is characterized by lifelong haemolytic anaemia and 
many other significant morbidities largely related to painful and debilitating vaso-occlusive 
phenomenon.(49)  
Patients present with recurrent anaemia, which sometimes require blood transfusion. 
‘Sicklers’, as affected persons are often called, have worsened symptoms of low packed cell 
volume especially when there is a co-infection or pregnancy. It is a challenge for patients in 
developing countries, both old and young, in treating their ill conditions as there are usually 
inadequate supportive measures to restore them back to their stable states.  
Thalassemia is the most common single genetic disorder worldwide, resulting from defects 
in genes producing hemoglobin. (50) It is highly prevalent in many Asian, Mediterranean 
and Middle Eastern countries.(51) The intermediate clinical forms of thalassemia result in 
anaemia, with occasional need for transfusions of red blood cells.(17) 
5. Prospects and challenges of diagnosis of underlying causes of anaemia  
Blood test for serum ferritin seems to be a sensitive and an early indicator of iron deficiency. 
In most developing countries, it is determined by using an immunoassay kit which is 
readily available, easily done and relatively inexpensive. (52) However, serum iron 
concentration, total iron-binding capacity and examination of blood films cannot detect the 
earliest stages of iron deficiency. (52) On the other hand, bone marrow examination showing 
absence of stainable iron is the definitive method for diagnosing IDA;(53) however, this is a 
painful and invasive procedure and it is therefore usually used as a last resort.(54) 
The World Health Organisation (WHO) recently recommended prompt parasitologic 
confirmation by microscopy or alternatively, by rapid diagnostic tests (RDTs) in all patients 
suspected of malaria before treatment is commenced unless parasitological diagnosis is not 
accessible; this is with a view to reducing cases of resistance to anti malaria treatment. (55) 
However, many peripheral health facilities in resource-poor settings of developing countries  
lack the capacity to conduct quality parasitological diagnosis of malaria by microscopy.(56-
57) Nonetheless, rapid diagnostic tests (RDTs) for malaria had recently been shown to offer 
the potential of extending accurate malaria diagnosis to areas when microscopy services are 
not available, especially in remote locations of the developing countries.(58-59)  
In making a diagnosis of any clinical phase of  schistosomiasis, the highly sensitive and 
specific PCR based assays have been developed for the detection of schistosome DNA in 
faeces or sera and plasma.(60) However, these tests are either not available or very 
expensive in many developing countries; thus, clinicians often use clinical acumen to make a 
diagnosis in majority of cases. Furthermore, fresh water bath is common among children in 
developing countries; thus, children with pruritic reaction or unexplained febrile illness 
several weeks after a fresh water bath are suspected to have contracted urinary 
schistosomiasis.(61) Diagnosis is made by finding parasitic eggs in urine sample, which is 
best taken at midday after exercise when most eggs are being shed.(61) On the other hand, 
eggs of hookworm are readily isolated from stool samples in developing countries. 
Major challenges facing laboratory systems in HIV testing in resource-poor settings include 
poor infrastructure, lack of human capacity, lack of laboratory policies, and limited 
synergies between clinical and research laboratories; these factors compromise the quality of 
test results and patient management.(62) In addition, HIV stigmatization is a major barrier 
preventing many people from having voluntary counseling and testing done in developing 
countries. For instance, in the prevention of maternal to child transmission programme 
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(PMTCT), challenges of diagnosis in developing countries include HIV-associated stigma. 
This has been reported to pose a barrier to service utilization, including failure of women to 
return for HIV test results where rapid testing is not available, low acceptance of short-
course preventive ARVs offered to HIV-positive women at antenatal clinics, difficulty in 
tracking and following up of mothers who deliver their infants at home and complexities of 
infant feeding for HIV-positive mothers in very low-resource settings.(63) 
The major challenge in the diagnosis of haemoglobin disorders is detection of the disease 
conditions during prenatal period. At this period, laboratory confirmation  is critically 
important to enable a couple at risk in making an informed decision about potential 
termination of pregnancy.(64) With DNA diagnostics, it has become possible to make 
definitive diagnoses of different haemoglobin disorders during the first trimester of 
pregnancy by analyzing foetal DNA obtained from chorionic villous biopsy. There is 
evidence that neonatal screening for sickle-cell anaemia, when linked to timely diagnostic 
testing, parental education and comprehensive care, markedly reduces morbidity and 
mortality from the disease condition in infancy and early childhood.(48, 65). 
6. Management of anaemia 
The objectives of management of anaemia include(1):  
 Treatment of the underlying cause; 
 Restoration of the haemoglobin concentration to normal levels; and  
 Prevention and treatment of complications.  
6.1 Treatment of the underlying cause of anaemia 
Iron deficiency anaemia is treated with oral iron supplements as ferrous sulfate, ferrous 
fumerate or ferrous gluconate given as 200 mg twice or three times daily. Treatment could 
also be parenteral as iron dextran, especially when there is intolerance to oral iron or 
anaemia is diagnosed late in pregnancy.  
Low birth weight infants are born with low iron stores; therefore, they demand high iron 
requirements for growth. Furthermore, their iron requirements cannot be readily met from 
breast milk and it is known that their iron stores are depleted by 2 to 3 months 
postpartum.(7) The global recommendation is to supply low birth weight infants with 
supplemental iron drops starting at 2 months of age.(38) A substantial amount of evidence 
confirms that iron supplementation of anaemic school children improves their school 
performance, verbal and other skills.(66) 
Vitamin A can be given as oral supplementation doses to postpartum mothers irrespective 
of their breastfeeding options in doses of 200,000 I.U and to less than 5 years of age in doses 
between 100,000-200,000 I.U. In some countries where vitamin A deficiency is a public 
health problem, vitamin A supplements in capsule form are administered during National 
Immunization Days (NIDs) alongside oral polio and measles vaccines.(67) Though, high 
supplementation dose of vitamin A is of immense benefit to both mother and breast feeding 
infant, it should be avoided in pregnant women because it can cause miscarriage and birth 
defects.(68)  
Vitamin B 12 is usually given intramuscularly but recent studies have shown that an oral 
dose is as effective as the injectable administration.(69) The daily requirement of vitamin 
B12 is approximately 2 mcg; the initial oral replacement dosage consists of a single daily dose 
of 1,000 to 2,000 mcg. 
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Folic acid supplementation can be given to patients with folate deficiency in doses between 
1-5 mg daily. It is routinely given to pregnant women, particularly early in pregnancy, to 
prevent neural tube defect in the growing foetus in some developing countries. Malaria is 
treated with a wide range of anti-malaria drugs and most African countries now 
recommend the Artemisinin-based combination therapy (ACT), which is given to reduce 
cases of resistance of the parasite to other drugs. 
Antihelminthic drugs such as albendazole or mebendale can be given to people infested with 
hookworm. In addition, iron deficiency aneamia which may co-exist can be treated with iron 
supplement. Praziquantel is the drug of choice for the treatment of schistosomiasis and it is 
shown to be effective and safe  in pregnancy.(36) Praziquantel can easily be administered 
according to height using a “dose pole” developed to dispense the drug at 40-60 mg/kg; this is 
with a view to minimizing under dosage while the “dose pole” helps in identifying five height 
intervals corresponding to 1½, 2 ,2½, 3 and 4 tablets of praziquantel.(70) 
The availability of the highly active antiretroviral therapy (HAART) at no cost has been of 
immense benefits to people living with HIV and AIDS, especially in developing countries 
where most affected persons cannot afford the drug treatment. Furthermore, WHO 
introduced revised treatment guidelines in 2010; these guidelines recommended early 
initiation of antiretroviral therapy, at a CD4 count of < 350 cells/mm3. This has, therefore,  
increased the total number of people medically eligible for antiretroviral therapy by about 
50% i.e. from 10 million to 15 million in 2009 globally.(42) The main aspect of care for 
persons affected by sickle cell anaemia involves early treatment intervention of preventable 
health problems such as analgesics, antibiotics, vitamins, folic acid supplementation and 
high fluid intake are periodically used.  
6.2 Restoration of the haemoglobin concentration to normal levels 
Generally, blood transfusion is a very important measure in the treatment of anaemia; but it 
should not be used as a substitute for specific treatment of the underlying cause.(1) Blood 
can be given as an autologous transfusion, exchange transfusion or direct transfusion with 
blood products. It is recommended that blood transfusion should be given only if the 
dangers of failure to transfuse outweigh those of transfusion. (1) In developing countries, 
problems such as economic constraints may limit blood safety precautions; thus, unsafe 
blood which ought to have been screed for infections such as HIV, hepatitis B or C and 
syphilis, is inadvertently transfused.(71)  
In addition, many developing countries do not have reliable testing systems because of staff 
shortage, lack of basic laboratory services, poor quality test kits or their irregular supply.(72) 
Sometimes, patients receive wrong blood type due to mismatch error and thereafter, 
develop blood transfusion reaction. These constraints underscore the importance of 
strengthening blood transfusion services in developing countries; furthermore, the process 
of obtaining an informed consent from patients, including discussing the risk and benefit of 
transfusion, except in life-threatening emergencies should be emphasised.(1) 
6.3 Prevention and treatment of complications 
Complications may arise as a result of the underlying disesase or anaemia itself. The overall 
goal is to ensure that anaemia does not re-occur or further deteriorates. Once the underlying 
cause can be treated, the prognosis is good in most cases. Other supportive measures 
include a balanced diet with adequate protein and vitamins; bed rest can also go a long way 
to restore blood levels in the body. 
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7. Strategies to prevent anaemia 
Food fortification and dietary diversification with iron are important measures to prevent 
iron deficiency anaemia(8), especially in the vulnerable groups such as pregnant women 
and children. A number of strategies are used to deliver additional iron to humans, but food 
fortification has the greatest potential to improve the iron status of the largest number of 
people.(7) Ferrous fumarate, ferrous succinate and small particle size iron are suitable iron 
fortificants for infant cereals.(73) Infant cereals are widely fortified in developed countries 
and this has resulted in a definite reduction in anaemia. (74)  WHO recommends that all 
pregnant women receive iron supplements of 60 mg daily combined in a pill, which also 
contains 400 μg folic acid.(75) 
In view of the high prevalence of Vitamin A deficiency  in developing countries and the 
potentially high prevalence of deficiencies of other micronutrients required for Hb synthesis 
and other functions, it is logical to assume that supplementation with multiple micronutrients, 
rather than just iron or iron plus folate, would be a rational public health strategy.(7) 
Currently, WHO recommends routine vitamin A supplementation during pregnancy or at any 
time during lactation in areas with endemic vitamin A deficiency.(76) Vitamin A can be given 
to children under 5 years of age in doses between 100,000-200,000 I.U as it is practised in some 
developing countries during national immunization days. Furthermore, absorption of iron 
from food can be enhanced by increasing intake of vitamin C.  
Vector control remains as the most effective measure to prevent transmission of malaria in 
developing countries; though the methods used may vary considerably in their 
applicability, cost and sustainability.(77) WHO had recommended a combination of 
integrated vector management, indoor residual spraying, insecticide treated material and 
larval control.(78) Insecticide-impregnated bed nets in communities decrease the prevalence 
of severe anaemia in young children.(7) The home management of malaria (HMM) strategy 
has been introduced where early recognition, and prompt and appropriate treatment of 
malaria illness in children under 5 years of age in the home or community can be achieved. 
If Plasmodium falciparum malaria is endemic and transmission of infection is high, women in 
their first or second pregnancies should be given curative antimalarials at their first prenatal 
visit followed by locally recommended antimalarial prophylaxis.(7) Malaria control 
programme is highly necessitated among the highly susceptible group especially in the 
tropical regions of the world.(7)  
In areas endemic with parasitic infections which affect Hb or iron status, the  International 
Nutritional Anemia Consultative Group (INACG), WHO, and United Nations Childrens’ 
Fund (UNICEF) recommended certain complementary control measures.(79) For example, 
adults and children over 5 years living in hookworm endemic areas (i.e. prevalence of 20-
30% and above) are required to be treated with at least an annual dose of albendazole, 
mebendazole, Levamisole or Pyrantel.  These drugs can be given to pregnant and lactating 
women, but should be avoided in the first trimester of pregnancy.(80)  
Other efforts aimed at controlling hookworm infections include sanitary disposal of faeces 
and educational campaigns on proper use of latrines.(81) Most at risk persons are those who 
engage in agriculture and fishing, and those who use unsafe water for household chores 
particularly girls and their mothers.(36) Therefore, primary health care measures such as 
hand washing and wearing of shoes in hookworm endemic areas can have a major impact 
on the prevalence of anaemia.(7) All forms of schistosomiasis including intestinal and 
urinary types can be treated with praziquantel effectively. Prevention is best achieved by 
eliminating water dwelling snails, which serve as natural reservoirs of the disease. 
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Effective HIV preventive interventions include condom use, provision of clean injecting 
equipment, standard precautions, blood safety and post exposure prophylaxis for 
occupational and non-occupational exposures.(82) Sickle cell anaemia can be prevented if 
couples at risk of having affected children can be identified by inexpensive and reliable 
blood test. Periodic prophylaxis against malaria, infections and other factors which may 
trigger discomfort could improve quality life of affected children.(48) 
8. Conclusion and recommendations 
In developing countries which are usually characterized by resource-limited settings, slow 
progress has been made toward reducing the prevalence of anemia; this is largely due to 
persistent micro-nutrient deficiencies, and high prevalence of parasitic diseases, HIV, sickle 
cell disease and thalassemia.(17) The best approach to preventing IDA in pregnancy is to 
ensure adequate maternal iron status early in pregnancy or preferably in the pre-
conceptional period.(83) Therefore, micronutrient supplements should be given not only to 
pregnant women but also to non-pregnant women of reproductive age and adolescent girls; 
this would reduce the prevalence of anaemia in the community and consequently, improve 
fertility and maternal health. 
The apparent failure to reduce the prevalence of anaemia in developing countries may be 
partly due to existing interventions, which are usually designed with the assumption that 
iron deficiency is the main cause.(84) Thus, other important causes of anaemia have been 
underestimated and neglected, and these have been on the increase. Therefore, adequate 
attention should be given to the emerging causes of anemia in developing countries such as 
HIV/AIDS and micronutrient deficiency 
The involvement of government of developing countries can effectively combine and 
balance the needs for programme implementation, monitoring and evaluation, research and 
community involvement. It is expected that the burden of anaemia will drastically reduce if 
adequate attention is paid to joint participation of all stakeholders in combating the burden 
in developing countries. Intervention programmes should address iron deficiency with the 
focus on both dietary quantity and quality of the micronutrient composition. Strategies 
which are required to improve nutrition knowledge and awareness of mothers and health 
workers may also be implemented. 
Ultimately, treating the underlying causes of anaemia is critical in eliminating anaemia in all 
age groups, particularly the vulnerable ones. Therefore, it becomes imperative that all 
stakeholders harmonize and coordinate their efforts in ensuring that the burden and 
prevalence of anaemia, and its causes are reduced to the barest minimum in all developing 
countries. 
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